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ABSTRACT 
Mefenamic acid (MFA), a potent non-steroidal anti-inflammatory drug (NSAID), has a low oral bioavailability due to poor 
aqueous solubility and insufficient dissolution. In order to improve the same, various techniques were employed viz., 
evaporative precipitation into aqueous solution (EPAS), spherical agglomeration (SA) and solid dispersion using solvent 
evaporation and melt mixing. The formulations were characterised by differential scanning calorimetry (DSC) and X-Ray 
powder diffractometry (XRD) and were investigated for drug content studies, solubility studies, in vitro study and in vivo 
evaluation of anti-inflammatory activity. The formulations of MFA prepared by spherical agglomeration technique have 
satisfactory good drug content and the formulations with SLS and HPMC show a significant increase in solubility in case 
of SA technique. In case of solid dispersion, all carriers show improvement in the dissolution rate of the drug The DSC 
studies show no change in the polymorphism in most of the formulations The XRD studies of the formulations show no 
change in their crystalline form. The formulation containing HPMC & SLS as drug carrier show better anti-inflammatory 
effect with comparison to pure drug confirming the improved bioavailability of this drug. 
 
Keywords: Mefenamic acid, evaporative precipitation into aqueous solution, spherical agglomeration, solid dispersion, 
dissolution. 
 
 
INTRODUCTION 
Poor aqueous solubility of drugs is a major limiting factor 
with many new drugs in their successful launch in market in 
spite of their potential pharmacokinetic activity. Poor 
solubility (less than 10 %) of a drug, leads to poor dissolution 
in the gastro intestinal tract (GIT) hence, incomplete and 
erratic absorption ultimately limits its clinical utility. Further, 
poorly soluble drugs are generally administered at much 
higher doses than the actual dose in order to achieve 
necessary drug plasma levels leading to increased adverse 
reaction & cost of therapy and often yields erratic 
pharmacological response and hence poor patient 
compliance. About 40 % of drugs being in the pipeline of 
pharmaceutical companies are poorly soluble, which 
emphasizes the need of a technique to overcome such  
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problems.
 [1] Poorly water-soluble drugs are associated with 
slow drug dissolution followed by slow absorption leading 
eventually to inadequate and variable bioavailability. 
Solubilty, one of the key parameter in BCS, as well as 
dissolution rate is the most essential fators controlling the 
rate and extent of drug absorption. A poorly water soluble 
compound is defined which get soluble less than 1part per 
10000 part of water. A poorly water soluble drug, more 
recently, has been defined in general terms which require 
more time to dissolve in the gastrointestinal fluid than it take 
to be absorbed in the gastrointestinal tract. Thus a greater 
understanding of dissolution and absorbation behaviors of 
drugs with low aqueous solubility is required to successfully 
formulate them into bioavailable drug products. 
[2] 
Mefenamic acid, a non steroidal anti-inflammatory drug was 
selected as model drug as the drug has low aqueous solubility 
where its GIT absorption is limited by its dissolution in the 
gastrointestinal fluids exhibiting a low bioavailability after 
oral administration. 
[3] A number of approaches are practiced 
to improve the aqueous solubility poorly soluble drugs viz., 
solid dispersion (solvent evaporation method, fusion process Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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melt- mixing, freeze-dried, fusion-solvent method, kneading 
technique, co precipitation), 
[4] spherical agglomeration, 
[5] 
evaporative precipitation in aqueous solution, 
[6] 
microcrystallisation, 
[7] supersaturation, 
[8] pro drug approach, 
[9] polymorphism, 
[10] complexation 
[11],  pH adjustment 
[12], 
co-solvents 
[13-14], use of surfactant 
[15] and particle size 
reduction. 
[16] These techniques result into polymorphic 
changes or changes in crystal structure or hydrophilicity or 
particle size changes due to formation of molecular 
dispersion. The formulations were evaluated by the 
evaluation techniques utilized also focused on studying these 
changes in drugs along with their solubility, dissolution and 
other properties. The solubility and in vitro study was 
evaluated by the spectrophotometer in the dissolution media. 
The polymorphic form of the formulation is evaluated by the 
differential scanning calorimetry (DSC) and crystal structure 
determination by the powder X-ray diffraction studies (XRD) 
at the different angles. The formulations of mefenamic acid 
were also evaluated by in vivo study by anti-inflammatory 
activity on wistar rats. In the present investigation the 
techniques utilized were Evaporative Precipitation into 
Aqueous Solution, Spherical agglomeration, Solvent 
evaporation and Melt-Mixing, mainly due to their ease in 
formulation and versatility in application. All these 
techniques can be easily accommodated at industrial level 
and the techniques can be easily incorporated in formulation 
operations in pharmaceutical industry. 
 
MATERIALS AND METHODS 
Materials 
Mefenemic acid (MFA) was obtained as gift sample from 
Martin & Brown Pharmaceutical Company, Hisar, India. 
Polyvinyl pyrrolidone K30 (PVP), 
Hydroxypropylmethylcellulose (HPMC) and Poly Ethylene 
Glycol (PEG-4000) were purchased from Qualigens Fine 
Chemicals (Mumbai, India). All other chemicals were of 
suitable analytical reagent grade. 
Methods 
Prepration of spherical agglomerates of PEG-4000, 
HPMC, SLS, PVP 
MFA (2.5 g) was dissolved in 40 ml DMF by gentle warming 
up to 50ºC and then cooled to room temperature. A solution 
of 0.1% w/v of surfactant/polymer (HPMC, PEG-4000, 
Sodium Lauryl Sulfate, PVP K-30) in distilled water (30 ml) 
was then added to drug solution in DMF with stirring (Table 
1). The precipitated solid was dissolved by further addition of 
30 ml DMF and gentle warming. This solution was added 
with stirring to 400 ml distilled water contained in the 
agglomerating vessel. Chloroform (18 ml) was added drop 
wise with stirring at 900 rpm for 30 min. The precipitate 
obtained was collected and dried in vacuum and stored in 
desiccator further studies. 
Preparation of solid dispersion by solvent evaporation 
technique 
In this technique the proper volume of two solutions were to 
be taken.  MFA (5 wt %) and polymer PEG/SLS/HPMC/PVP 
(5 wt %), in ethanol were mixed and the mixtures were 
stirred for 10 minutes at 900 rpm (Table 1). The final 
solutions were poured onto Petri dish and the solvent was left 
to evaporate in open air for 2 days. After complete removal 
of the solvent the solid dispersions were stored at ambient 
temperature in desiccator. 
Preparation of hydrophilic coated drug particles by 
evaporative precipitation in aqueous solution (EPAS) 
method 
Preheated (≅70ºC) organic solution of the MFA in 
Chloroform (1%) is sprayed though a fine nozzle into a 
preheated (≅70ºC) (1 %) aqueous solution of 
surfactant/polymer. The rapid evaporation of the organic 
solvent produces high supersaturation and rapid precipitation 
of the drug in the form of a colloidal suspension that is 
stabilized by a variety of low molecular weight 
surfactant/polymer solution of (SLS, PEG-4000, PVP, and 
HPMC). The suspensions were then freeze dried (Table 1). 
Preparation of solid dispersions by melt mixing method 
A physical mixture of MFA and PEG were heated during 
stirring in a reaction tube immersed in an oil bath to 130°C. 
When the drug was completely melted and a homogeneous 
solution was obtained. Solid dispersions with Drug/PEG 
20/80, 40/60, 60/40 weight ratios were prepared (Table 1). 
Next, the tubes were immersed in a water bath to quench the 
melt. The prepared samples were dried and stored at 25°C in 
desiccator. 
EVALUATION AND CHARACTERIZATION 
Differential Scanning Calorimetry 
DSC studies of the prepared samples were conducted 
immediately after preparation as well as after storage for 6 
months. An instrument (DSC Q10, TA Instruments, U.S.A) 
equipped with an intraocular 2p cooling accessory was used. 
Samples of 10 mg to 5 mg were placed in saturated 
aluminum pans and sealed with a lid. Heating scans by 10ºC 
/min applied with a purge of 50 ml/min. Fast heating rates are 
preferred to prevent changes during scanning. 
X-Ray Powder Diffractometry 
X-ray powder diffraction patterns were recorded on a 
XPERTO-PRO X-ray diffractometer using Ni filtered, using 
a voltage of 45 kV, and a 40 mA current. The scanning 
scheme employed was 1 min- 1 over the 6 to 50 diffraction 
angle (2θ) range. The relationship used for the calculation of 
crystallinity was presented by relative degree of crystallinity. 
[17]
Relative degree of crystallinity (RDC) =  
⎥
⎥
⎦
⎤
⎢
⎢
⎣
⎡
ref
sam
I
I
 
Where, Isam=Peak height of the sample under investigation 
Iref =Peak height at the same angle for the reference with the 
highest intensity. 
Drug Content Studies 
The individual formulations equivalent to 10 mg of MFA 
were weighed accurately and mixed with 100 ml of 
methanol. After that the solutions is to be 10 times diluted 
with methanol. The suspension was filtered through 22 µm 
nylon disc filters and drug content was analyzed at 284 nm 
using UV Spectrophotometer (Perkin Elmer EZ301, USA).   
Solubility Studies 
In solubility study of the drug and its formulations was done 
by shaking 10 mg of MFA and its formulations (equivalent to 
10 mg drug) with 40ml of distilled water (0.1 %) in 100ml 
volumetric flask for 24 hours on water bath shaker and then 
the volume was made up to 100 ml. One ml of this solution 
was diluted 10 times with distilled water and the absorbance 
was measured at 284 nm using UV Spectrophotometer. Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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Table 1: Composition of various formulation batches (MFA 01-16) 
containing 10 mg of Mefenamic acid 
S. 
No  Formulations Techniques  Solvent  Polymers/ 
Surfactant 
1 MFA-01  SA  DMF  HPMC 
2 MFA  -02  SA  DMF  PVP 
3 MFA  -03  SA  DMF  PEG-4000 
4 MFA  -04  SA  DMF  SLS 
5 MFA  -05  SE  Ethanol  HPMC 
6 MFA  -06  SE  Ethanol  PVP 
7 MFA  -07  SE  Ethanol  PEG-4000 
8 MFA  -08  SE  Ethanol  SLS 
9 MFA  -09  EPAS  Chloroform  HPMC 
10 MFA  -10  EPAS  Chloroform  PVP 
11 MFA  -11  EPAS  Chloroform  PEG-4000 
12 MFA  -12  EPAS  Chloroform  SLS 
13 MFA  -13  MM  NO  PEG-4000 
14 MFA  -14  MM  NO  PEG-4000 
15 MFA  -15  MM  NO  PEG-4000 
16 MFA  -16  STD  NO  NO 
 
Table 2:Content, solubility and % release of Mefenamic acid from 
different formulations in comparison with original drug 
S. 
No  Formulations  % drug 
content 
Solubility 
(µg/ml) 
% drug released 
after 6 h 
1 MFA-01 56.1±0.30  5.54±0.03  49.7±0.04 
2 MFA  -02 80.7±0.65  2.01±0.02  23.1±0.04 
3 MFA  -03 80.6±0.25  4.29±0.03  35.1±0.07 
4 MFA  -04 77.1±0.25  6.51±0.01  62.9±0.08 
5 MFA  -05 49.8±0.15  3.71±0.04  35.4±0.02 
6 MFA  -06 43.2±0.20  4.35±0.06  44.9±0.06 
7 MFA  -07 43.3±0.65  4.12±0.04  32.7±0.04 
8 MFA  -08 51.0±0.30  5.23±0.02  51.1±0.03 
9 MFA  -09 35.2±0.25  3.37±0.03  32.8±0.04 
10 MFA  -10  20.1±0.20 2.92±0.03  26.5±0.03 
11 MFA  -11  28.8±0.40 5.47±0.02  57.6±0.05 
12 MFA  -12  26.1±0.60 6.07±0.01  50.6±0.03 
13 MFA  -13  53.9±0.50 5.92±0.03  53.8±0.04 
14 MFA  -14  54.3±0.10 2.82±0.04  31.9±0.03 
15 MFA  -15  63.8±0.30 2.72±0.04  24.9±0.04 
16 MFA  -16  100±0.00 3.02±0.03  27.3±0.05 
 
In Vitro Study 
The dissolution study is to be done of the10 mg of MFA and 
its formulations (equivalent to 12 mg drug). Formulations (10 
mg of MFA) were placed in capsule with 200 mg sprayed 
dried lactose in a rotating basket (USP XXII) and then placed 
in 900 ml 0.1% SLS solution and stirred at a speed of 50 rpm 
with temperature maintained at 37 ± 1ºC. Aliquots of 10ml 
were withdrawn at appropriate time intervals and an equal 
volume of 0.1 % SLS was replaced in the vessel. MFA in the 
aliquot was assayed at 284 nm using UV Spectrophotometer. 
Evaluation of Anti-Inflammatory Activity of Mefenemic 
Acid 
The anti-inflammatory activity of MFA and its formulations 
were evaluated by carrageenan induced rat paw oedema 
method. The present method was assessed by inhibition of 
oedema caused by carrageenan. Experimental protocol was 
approved by the institutional animal ethics committee 
(IAEC) and care of animals was taken as per the guidelines 
of Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Ministry of Forest and 
Environment, Govt. of India. 
Experimental Animals: The experiment was carried out on 
healthy Wistar rats weighing between 120-200 g of either 
sex. The rats were divided by randomization into 10 groups. 
Each group comprised of 6 animals. The animals were fasted 
with free access to water for 12 h prior to the tests. 
Drug and dose: All the standard and test drugs were 
suspended with 0.5 % w/v CMC. 
(a) Control groups: 0.5 % w/v CMC (10 kl/kg) alone. 
(b) Standard group: Standard group of animals received 
MFA (12 mg/kg). 
(c) Test group: Test group of rats received first dose as equal 
to parent drug’s dose. 
Oedematogenic agent: 0.1 ml of a 1 % saline freshly 
prepared suspension of carrageenan in normal saline solution 
of (0.9 % w/v) was used as oedematogenic agent to induced 
swelling or inflammation in paw of rats. 
Route of administration : All the drugs or standard or 
vehicle were administrated to rats by oral route while 0.1 ml 
of 0.1 % w/v carrageenan solution was injected 
subcutaneously (s.c.) under the planter surface (subplanter) 
of left hind paw. 
Procedure: Different groups of animals were treated with 
test drugs or standard or vehicle for anti-inflammatory 
studies. One carageenan was injected subcutaneously to the 
right hind paw of each rat. The thickness (mm) 0f the paw 
was measured immediately and at 1, 2, 3 and 4 h intervals 
after the injection of the carageenan. A digital vernier caliper 
(Aerospace, china) used of inflammation was calculated for 
the MFA and their formulations by following formula. 
Edema (ΛT) and inhibition rate (I) were calculated as 
followed: 
ΛT = Tt –To 
% inflammation = ΛT/To *100 
% Inhibition = 100 - % inflammation 
Where, Tt = the left hind paw thickness at time t, 
To = the left hind paw thickness before sub-planter injection 
of   carrageenan. 
[18, 10]
Statistical Analysis 
All the results were expressed as Mean ± Standard deviation 
(SD). Data was analyzed using one-way ANOVA followed 
by Turkey-Kramer multiple comparisons test. P<0.05 was 
considered as statically significant. 
 
RESULTS AND DISCUSSION 
Differential scanning calorimetric (DSC) study  
DSC thermograms of pure drug and corresponding drug 
carrier system are depicted in Fig. 1. The DSC curve of 
Mefenamic Acid (MFA-16) shows a sharp endothermic peak 
(Tpeak = 230.5°C) corresponding to its melting, indicating 
its crystalline nature. However, the characteristic 
endothermic peak, corresponding to drug melting was 
broadened and shifted toward lower temperature, with 
reduced intensity, in formulations MFA-01, MFA-07, MFA-
012, and MFA-13. This could be attributed to higher polymer 
concentration and uniform distribution of drug in the crust of 
polymer, resulting in complete miscibility of molten drug in 
polymer. No significant difference in DSC pattern of 
dispersions and physical mixture suggests that the kneading 
process could not induce interaction at the molecular level 
and solid dispersion formed is a physical mixture with highly 
dispersed drug crystals in polymeric carrier system. 
X-ray Diffraction Study 
XRD spectra of pure compound and binary systems with 
carriers are presented in Fig. 2. The X-ray diffractogram of 
mfa-16 has sharp peaks at diffraction angles (2θ) 21.37°, 
26.33°, 15.92°, and 20.14º. It is showing a typical crystalline 
pattern. However, all major characteristic crystalline peaks 
appear in the diffractogram of all the formulations (MFA-01, 
MFA-07 and MFA-12). Pure drug peak at 21.37° (2θ) was 
used for calculating RDC of formulations of mefenamic acid. 
The RDC values of MFA-01, MFA-07 and MFA-12 were Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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0.9772, 0.6031 and 0.5886, respectively. Moreover, the 
relative intensity and 2θ angle of these peaks remains 
practically unchanged.  
Table 3: Anti-inflammatory activity of Mefenamic acid and its formulations 
Oedema (∆T) (Mm) ± SD  % Inhibition  Treatment  Dose 
(mg/Kg)  1 H  2 H  3 H  4 H  1 H  2 H  3 H  4 H 
Control  -  1.77 ± 0.07  2.03 ± 0.03  3.22 ± 0.04  3.35 ± 0.03  0.00  0.00  0.00  0.00 
Vehicle (HPMC)  12  1.71 ± 0.02  2.30 ± 0.02  3.19 ± 0.02  3.22 ± 0.02  0.00  0.00  0.00  0.00 
Vehicle (SLS)  12  1.69± 0.06  2.39 ± 0.05  3.21 ± 0.05  3.24 ± 0.06  0.00  0.00  0.00  0.00 
MFA-16  12  1.30 ± 0.02*
￿ 1.20± 0.02*
￿ 1.14± 0.02*
￿ 1.32 ± 0.02*
￿ 45.38  49.58  52.11  44.54 
MFA-01  12  1.28 ± 0.02*
￿￿ 1.20± 0.02*
￿￿ 1.04± 0.02*
￿￿ 1.07 ± 0.03*
￿￿ 41.02  44.71  52.08  50.7 
MFA-04  12  1.20± 0.03*  1.15 ± 0.02*  0.92± 0.02*  1.02 ± 0.02*  45.46  47.73  58.19  53.64 
MFA-08  12  1.22± 0.02*
￿￿ 1.03± 0.02*
￿￿ 0.91± 0.02*
￿￿ 1.02 ± 0.02*
￿￿ 42.19  51.19  56.88  53.61 
MFA-09  12  1.63 ± 0.02*
￿￿ 1.44± 0.02*
￿￿ 1.32± 0.02*
￿￿ 1.36 ± 0.03*
￿￿ 27.24  35.72  41.08  39.29 
MFA-12  12  1.59 ± 0.02*
￿￿ 1.41± 0.02*
￿￿ 1.31± 0.02*
￿￿ 1.34 ± 0.03*
￿￿ 28.7  36.78  41.25  39.49 
Oedema Is Expressed As Mean Change In Paw Thickness ± SD 
N =6 Animals. 
* P < 0.001 As Compared To Control. 
￿ P < 0.01 
￿￿ P < 0.001 As Compared To Mefenamic 
 
 
Fig. 1: DSC thermogram of pure Mafenamic acid and its formulations Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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Fig. 2: Powder X-Ray diffraction spectra of pure Mafenamic acid, MFA-01, MFA-07 and MFA-12 
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Fig. 3: Solubility studies of Mefenamic acid (MFA 16) and its formulations 
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Fig. 4: Dissolution profile of pure Mefenamic acid (MFA 16) and its formulations prepared by spherical agglomeration (MFA 1 – MFA 4) Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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Fig. 5: Dissolution profile of pure Mefenamic acid (MFA-16) and its formulations prepared by solvent evaporation (MFA-5 – MFA-8) 
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Fig. 6: Dissolution profile of pure Mefenamic acid (MFA 16) and its formulations prepared by evaporative precipitation into aqueous solution (MFA 
09 – MFA 12) 
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Fig. 7: Dissolution profile of pure Mefenamic acid (MFA 16) and its formulations prepared by melt mixing (MFA 13 – MFA 15) 
 
Drug content study 
The drug content of the prepared formulations of MFA was 
observed to be varying from 80.7 to 20.1 % and it was 
maximum with formulation (MFA-02) and minimum in 
formulation  (MFA-10) as shown in Table 2. This studies 
shows that spherical agglomeration technique shows the 
maximum drug content and the Evaporative precipitation in 
aqueous solution (EPAS) show the minimum drug content.  Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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Solubility studies 
Aqueous solubility of MFA was observed to be maximum 
with formulation MFA-04 (6.51±0.01 µg/ml) and the 
minimum with formulation MFA-02  (2.01±0.02 µg/ml) as 
shown in Table 2 and Fig. 3. Studies show that spherical 
agglomeration technique shows the maximum solubility with 
SLS surfactant and where as with PVP this technique show 
minimum drug solubility. In the solid dispersion (solvent 
evaporative) technique the formulations MFA-08 show 
maximum (5.23µg/ml) and formulations MFA-05 show the 
slightly more drug solubility as compared to the pure drug. In 
the Evaporative Precipitation technique in Aqueous Solution 
the formulation MFA-12 and MFA-11 show the much more 
solubility (6.07±0.01 and 5.47±0.02 µg/ml respectively). And 
the formulation MFA-10 shows the minimum solubility as 
compared to the MFA-16. In the solid dispersion (Melt 
Mixing) technique the formulations MFA-13 show maximum 
drug solubility is 5.92±0.03 µg/ml. Over all in the solubility 
studies show that the spherical agglomeration technique and 
EPAS is the best method for the increases in the solubility of 
the mefenamic acid with SLS. 
In vitro dissolution studies 
In vitro dissolution studies of the prepared formulations were 
done on USP-I apparatus using baskets. The specifications 
used for dissolution study of the all the prepared formulations 
were same and described below. In all the formulation, the 
drug content was taken as 10 mg per capsule in 900 ml 
dissolution medium, 37°C containing SLS (0.5 % w/v) and at 
different time intervals, 10 ml of the solution was withdrawn 
until 16 h. 
In vitro dissolution study of the different formulations of 
MFA prepared by spherical agglomeration technique, it was 
observed that the formulation MFA-04, MFA-01 show the 
increase in the % release of the drug from the formulations. 
The formulation MFA-02 Show the lesser % release of the 
drug in the dissolution medium. In Solid Dispersion (Solvent 
Evaporation) technique, it was observed that the formulation 
MFA-08, MFA-06 and MFA-05 show the increase in the % 
release of the drug from the formulations.  In EPAS 
technique, it was observed that the formulations  MFA-11, 
MFA-12 show the increase in the % release of the drug from 
the formulation which are to be kept in the capsule as 
compared to the std. drug profile. The formulation MFA-10 
Show the lesser % release of the drug in the dissolution 
medium. 
In Solid Dispersion technique (Melt Mixing), it was observed 
that the formulation MFA-13, MFA-12 show the maximum 
increase in the % release of the drug from the formulation 
which are to be kept in the capsule as compared to the MFA 
profile. The formulation MFA-15 show the lesser % release 
of the drug in the dissolution medium as compared to the 
MFA release profile as shown in Fig. 4-7 and Table 2. 
Effect of different carriers on the dissolution of 
Mefenamic acid 
Spherical agglomeration techniques were developed for 
improving the solubility of microcrystalline mefenamic acid. 
The process involved agglomerating microcrystal using 
agglomerating solvents. Temperature and speed of agitation 
were optimized to obtain spherical agglomerates in a desired 
range, which was found to be essential to enhance the 
solubility. Incorporation of polymer/surfactant (HPMC, SLS) 
during agglomeration significantly enhanced the dissolution 
rate of mefenamic acid. In additional flow and 
compressibility properties of the drug is improved. 
The enhancement of dissolution of drug from drug carrier 
systems can be ascribed to several factors. The mechanism of 
dissolution rate improvement from solid dispersion is lack of 
crystallinity and particle size reduction considered to be 
important factors for dissolution rate enhancement. Mixing of 
drug with a hydrophilic carrier results in greater wetting and 
increase surface available for dissolution by reducing 
interfacial tension between the hydrophilic drug and 
dissolution media. It was noted that drug carrier system sink 
immediately, while pure drug keeps floating on the surface 
for a longer time interval and similar results were reported by 
Modi et al. 
[19]
The dissolution parameters of solid dispersion of MFA with 
various carriers (HPMC, PVP K-30, PEG-4000, SLS) were 
carried with same concentration of each carrier. The 
dissolution rate of pure drug is low even in the surfactant 
based medium, as 27.3 % of the drug gets dissolved 360 min 
respectively. 
Solid dispersions formulated with all the carriers exhibited 
significant improvement in the dissolution parameters of 
drug. The order of dissolution enhancement with various 
binary systems was found to be (MFA-08>MFA-06>MFA-
05>MFA-07) for mefenamic. The increase in the dissolution 
rate of the solid mixtures might be due to size reduction and 
increase in the wettability of the drug molecules in presence 
of the surfactants. This kind of technique can be extended for 
improvement dissolution rate of drug showing poor 
dissolution profiles and causing erratic bioavailability. 
[20]
In evaporative precipitation into aqueous solution (EPAS) to 
form micron to sub-micron sized particles, leading to 
increased bioavailability relative to larger particles. Soluble 
stabilizers offer the ability to form submicron particles that 
have high dissolution rates in aqueous media. The present 
invention often produces particles having reduced 
crystallinity as compared to the bulk drug, which enhances 
dissolution. 
[21]
Anti-inflammatory activity of mefenamic acid and its 
formulations 
Table 3 shows the anti-inflammatory activity of MFA and its 
formulations after oral administration. Mefenamic acid and 
its formulations i.e. MFA-01, MFA-04, MFA-05, MFA-08, 
MFA-09 and MFA-12 exhibited their maximum anti-
inflammatory effect at 3 h. MFA-4 and MFA-08 inhibited 
maximum edema formation (58.19%) and (56.88%) 
respectively after 3 h when compared with control animals. 
MFA-4 and MFA-08 has better activity as compared to 
MFA. At 3 h both formulations gave a significant inhibition 
of oedema formation. MFA and its formulations produced 
significant better activity (p<0.001) when compared with 
control. 
Spherical agglomeration is a better technique for the 
solubility enhancement of MFA because the drug loaded to 
the carriers in very significant amounts due to which the 
bulkiness of the dosage form is reduced and the solubility 
and oral bioavailability of the drug improved nearly twice the 
pure drug. The EPAS techniques also gave better results in 
the in vitro studies but their limitation is that the drug content 
in the formulations is very less, so it enhances the bulkiness 
of the dosage form. Present investigation successfully 
enhanced the solubility and dissolution profile of the Singh et al. / Application of Some Novel Techniques for Solubility Enhancement …………. 
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investigational drug there by enhancing the bioavailability of 
drugs and improving the patient compliance. 
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